LOS ANGELES, CA / ACCESSWIRE / January 25, 2021 / Mosaic Laboratories (Mosaic), a leading provider of pathology-focused pre-clinical and clinical trial services to pharmaceutical and biotechnology companies, has been acquired by Caprion-HistoGeneX, a leading provider of specialized precision medicine lab services to the biopharmaceutical industry. Backed by private equity firm Arsenal Capital Partners, Caprion-HistoGeneX plans to expand its histological biomarker franchise and further strengthen its North American base for assay development and deployment with this acquisition. Enthusiastic about combining forces, Mosaic Co-Founder Chris Kerfoot said: "We have developed a world-class, science-led organization and are ready to expand globally with new services that will help us in our mission to support our clients in the war on cancer."
Founded in 2005, Mosaic pioneered multiplex immunohistochemistry (IHC) with spectral imaging, and the company is recognized for its outstanding services for the development, validation, and implementation of complex IHC, in situ hybridization and FISH assays, positioning itself as one of the most prominent and comprehensive providers in the field. Its core capabilities include study design, assay development and deployment, data interpretation, and services to support exploratory biomarker analysis at pre-clinical and clinical trial stages, thereby enabling timely decisions for patient selection.
"Caprion-HistoGeneX is a perfect fit for us because of their global reach and deep infrastructure resources that will enhance Mosaic's positioning to serve the global pharma industry on a much larger scale," said Lisa Dauffenbach, Mosaic Co-Founder. Intrepid Investment Bankers (Intrepid), a Los Angeles-based M&A firm, served as the financial advisor to Mosaic. "Intrepid provided expert guidance, advising us at every stage of the journey. Their team understood Mosaic's strong values and goals, and their deep expertise in healthcare M&A was invaluable," added Dauffenbach.
"Chris and Lisa have done an outstanding job establishing Mosaic as a globally recognized leader in precision biomarker research with exceptional scientific talent, all validated by their top-tier client relationships. We are honored to have played a role in this combination that will further advance precision medicine," said Adam Abramowitz, Managing Director and Co-Head of Healthcare at Intrepid.
Caprion-HistoGeneX partners with the most prominent global pharma and biotech companies to provide immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. Under the leadership of Arsenal, Montreal, Canada-based Caprion joined forces with Antwerp, Belgium-based HistoGeneX in 2019, creating an integrated global leader in precision medicine and biomarker development. The acquisition of Mosaic provides a solid North American base for Caprion-HistoGeneX's assay development and deployment, expands the volume of pathology services, and positions the company as an emerging world leader of histological biomarker analysis for global clinical trials.
"Intrepid's Healthcare team identified key resources to assist in the transaction preparation phase, completed an extensive outreach which yielded tremendous interest, and helped us thoughtfully navigate the deal process during a complex COVID environment. As a result, we found an ideal strategic partner to enable us to achieve our global vision to increase our impact on the future of patient therapy," further commented Kerfoot.
"Mosaic has become one of the most sought-after analytical lab services partners in the clinical trial world. It was a privilege to help Chris and Lisa on this transaction that can position their company to unlock its full potential," commented Jonathan Bluth, Director and Co-Head of Healthcare at Intrepid.
Kerfoot and Dauffenbach will remain shareholders and senior executives with Caprion-HistoGeneX to build upon Mosaic's industry leadership in complex analytical services by adding Caprion-HistoGeneX's global strengths in specialized flow cytometry immune monitoring, quantitative mass spectrometry proteomics services, pathology, and biomarker assessment services.
Deal Team Contacts
Adam Abramowitz
Managing Director, Co-Head of Healthcare
aabramowitz@intrepidib.com
Jonathan Bluth, Director
Co-Head of Healthcare
jbluth@intrepidib.com
Kyle Berkman
Vice President
kberkman@intrepidib.com
About Intrepid Investment Bankers
Intrepid provides M&A, capital raising, and strategic advisory services to entrepreneurs and middle-market companies in various industry sectors. Our heritage breeds a culture that embraces teamwork, tenacity, and creativity to help our clients win big. We believe that every company has an entrepreneurial passion that drives it and a story that defines it. Our team delivers results through skillful positioning and relentless execution. Based in Los Angeles, Intrepid augments its international capabilities through its active participation in Oaklins, an exclusive global alliance of M&A advisory firms.
About Intrepid's Healthcare Group
Intrepid's Healthcare Group is dedicated to providing strategic advice in capital raises and mergers and acquisitions across a broad range of healthcare sectors, including physician practice management, diagnostics and labs, revenue cycle management, behavioral health, hospitals, IT, pharmacy, post-acute care, and medical devices. Our team maintains extensive relationships with strategic buyers and institutional investors across these sectors.
Investment banking services offered by Intrepid Investment Bankers LLC, a subsidiary of MUFG Union Bank. Member FINRA/SIPC.
SOURCE: Intrepid Investment Bankers
View source version on accesswire.com:
https://www.accesswire.com/625505/Mosaic-Laboratories-Acquired-by-Caprion-HistoGeneX-Transaction-Will-Fuel-Global-Expansion-and-Services-to-Pharmaceutical-Clients-on-Larger-Scale
